US Patent Issued to Centre for Addiction and Mental Health on May 26 for "Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors" (Canadian Inventors)

ALEXANDRIA, Va., May 26 -- United States Patent no. 12,636,291, issued on May 26, was assigned to Centre for Addiction and Mental Health (Toronto).

"Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors" was invented by Thomas D. Prevot (Toronto), Mounira Banasr (Toronto) and Etienne Sibille (Toronto).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides methods and related compositions for preventing neurocognitive decline associated with chronic stress, age, and neurodegenerative diseases. The methods described here are based upon the use of alpha5-GABAA receptor agonists to slow or prevent deleterious morphological changes in dendrites of the hippocampus ...